Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

White matter hyperintensities are more highly associated with preclinical Alzheimer's disease than imaging and cognitive markers of neurodegeneration.

Kandel BM, Avants BB, Gee JC, McMillan CT, Erus G, Doshi J, Davatzikos C, Wolk DA.

Alzheimers Dement (Amst). 2016 Apr 7;4:18-27. doi: 10.1016/j.dadm.2016.03.001. eCollection 2016.

2.

Meeting physical activity recommendations may be protective against temporal lobe atrophy in older adults at risk for Alzheimer's disease.

Dougherty RJ, Ellingson LD, Schultz SA, Boots EA, Meyer JD, Lindheimer JB, Van Riper S, Stegner AJ, Edwards DF, Oh JM, Koscik RL, Dowling MN, Gallagher CL, Carlsson CM, Rowley HA, Bendlin BB, Asthana S, Hermann BP, Sager MA, Johnson SC, Okonkwo OC, Cook DB.

Alzheimers Dement (Amst). 2016 Apr 9;4:14-7. doi: 10.1016/j.dadm.2016.03.005. eCollection 2016.

3.

The C677T variant in MTHFR modulates associations between blood-based and cerebrospinal fluid biomarkers of neurodegeneration.

Roussotte FF, Narr KL, Small GW, Thompson PM; Alzheimer’s Disease Neuroimaging Initiative.

Neuroreport. 2016 Aug 17;27(12):948-51. doi: 10.1097/WNR.0000000000000636.

4.

Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes.

Weston PS, Paterson RW, Modat M, Burgos N, Cardoso MJ, Magdalinou N, Lehmann M, Dickson JC, Barnes A, Bomanji JB, Kayani I, Cash DM, Ourselin S, Toombs J, Lunn MP, Mummery CJ, Warren JD, Rossor MN, Fox NC, Zetterberg H, Schott JM.

Alzheimers Dement (Amst). 2015 Nov 2;1(4):440-446. eCollection 2015 Dec.

5.

Is amyloid-β harmful to the brain? Insights from human imaging studies.

Jagust W.

Brain. 2016 Jan;139(Pt 1):23-30. doi: 10.1093/brain/awv326. Epub 2015 Nov 27. Review.

6.

Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community.

Petersen RC, Wiste HJ, Weigand SD, Rocca WA, Roberts RO, Mielke MM, Lowe VJ, Knopman DS, Pankratz VS, Machulda MM, Geda YE, Jack CR Jr.

JAMA Neurol. 2016 Jan;73(1):85-92. doi: 10.1001/jamaneurol.2015.3098. Erratum in: JAMA Neurol. 2016 Apr;73(4):481.

7.

Characterising the grey matter correlates of leukoaraiosis in cerebral small vessel disease.

Lambert C, Sam Narean J, Benjamin P, Zeestraten E, Barrick TR, Markus HS.

Neuroimage Clin. 2015 Aug 13;9:194-205. doi: 10.1016/j.nicl.2015.07.002. eCollection 2015.

8.

Relationship between cerebrospinal fluid biomarkers of Alzheimer's disease and cognition in cognitively normal older adults.

Pettigrew C, Soldan A, Moghekar A, Wang MC, Gross AL, O'Brien R, Albert M.

Neuropsychologia. 2015 Nov;78:63-72. doi: 10.1016/j.neuropsychologia.2015.09.024. Epub 2015 Sep 21.

9.

Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge.

Cash DM, Frost C, Iheme LO, Ünay D, Kandemir M, Fripp J, Salvado O, Bourgeat P, Reuter M, Fischl B, Lorenzi M, Frisoni GB, Pennec X, Pierson RK, Gunter JL, Senjem ML, Jack CR Jr, Guizard N, Fonov VS, Collins DL, Modat M, Cardoso MJ, Leung KK, Wang H, Das SR, Yushkevich PA, Malone IB, Fox NC, Schott JM, Ourselin S.

Neuroimage. 2015 Dec;123:149-64. doi: 10.1016/j.neuroimage.2015.07.087. Epub 2015 Aug 11.

10.

Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force.

Vellas B, Bateman R, Blennow K, Frisoni G, Johnson K, Katz R, Langbaum J, Marson D, Sperling R, Wessels A, Salloway S, Doody R, Aisen P; Task Force Members.

J Prev Alzheimers Dis. 2015 Jun;2(2):128-135.

11.

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, Donohue MC, Green RC, Harvey D, Jack CR Jr, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw L, Thompson PM, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Jul;11(7):865-84. doi: 10.1016/j.jalz.2015.04.005. Review.

12.

Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2.

Jack CR Jr, Barnes J, Bernstein MA, Borowski BJ, Brewer J, Clegg S, Dale AM, Carmichael O, Ching C, DeCarli C, Desikan RS, Fennema-Notestine C, Fjell AM, Fletcher E, Fox NC, Gunter J, Gutman BA, Holland D, Hua X, Insel P, Kantarci K, Killiany RJ, Krueger G, Leung KK, Mackin S, Maillard P, Malone IB, Mattsson N, McEvoy L, Modat M, Mueller S, Nosheny R, Ourselin S, Schuff N, Senjem ML, Simonson A, Thompson PM, Rettmann D, Vemuri P, Walhovd K, Zhao Y, Zuk S, Weiner M.

Alzheimers Dement. 2015 Jul;11(7):740-56. doi: 10.1016/j.jalz.2015.05.002.

13.

2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, Green RC, Harvey D, Jack CR, Jagust W, Luthman J, Morris JC, Petersen RC, Saykin AJ, Shaw L, Shen L, Schwarz A, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Jun;11(6):e1-120. doi: 10.1016/j.jalz.2014.11.001. Review.

14.

Alzheimer's disease first symptoms are age dependent: Evidence from the NACC dataset.

Barnes J, Dickerson BC, Frost C, Jiskoot LC, Wolk D, van der Flier WM.

Alzheimers Dement. 2015 Nov;11(11):1349-57. doi: 10.1016/j.jalz.2014.12.007. Epub 2015 Apr 24.

15.

Apathy is associated with lower inferior temporal cortical thickness in mild cognitive impairment and normal elderly individuals.

Guercio BJ, Donovan NJ, Ward A, Schultz A, Lorius N, Amariglio RE, Rentz DM, Johnson KA, Sperling RA, Marshall GA.

J Neuropsychiatry Clin Neurosci. 2015 Winter;27(1):e22-7. doi: 10.1176/appi.neuropsych.13060141. Epub 2014 Nov 10.

16.

Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease.

Wang L, Benzinger TL, Hassenstab J, Blazey T, Owen C, Liu J, Fagan AM, Morris JC, Ances BM.

Neurology. 2015 Mar 24;84(12):1254-60. doi: 10.1212/WNL.0000000000001401. Epub 2015 Feb 25.

17.

Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.

Vos SJ, Verhey F, Frölich L, Kornhuber J, Wiltfang J, Maier W, Peters O, Rüther E, Nobili F, Morbelli S, Frisoni GB, Drzezga A, Didic M, van Berckel BN, Simmons A, Soininen H, Kłoszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, Muscio C, Herukka SK, Salmon E, Bastin C, Wallin A, Nordlund A, de Mendonça A, Silva D, Santana I, Lemos R, Engelborghs S, Van der Mussele S; Alzheimer’s Disease Neuroimaging Initiative, Freund-Levi Y, Wallin ÅK, Hampel H, van der Flier W, Scheltens P, Visser PJ.

Brain. 2015 May;138(Pt 5):1327-38. doi: 10.1093/brain/awv029. Epub 2015 Feb 17.

18.

The evolution of preclinical Alzheimer's disease: implications for prevention trials.

Sperling R, Mormino E, Johnson K.

Neuron. 2014 Nov 5;84(3):608-22. doi: 10.1016/j.neuron.2014.10.038. Epub 2014 Nov 5. Review.

19.

Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals.

Mormino EC, Betensky RA, Hedden T, Schultz AP, Amariglio RE, Rentz DM, Johnson KA, Sperling RA.

JAMA Neurol. 2014 Nov;71(11):1379-85. doi: 10.1001/jamaneurol.2014.2031.

20.

Aging, neurodegenerative disease, and traumatic brain injury: the role of neuroimaging.

Esopenko C, Levine B.

J Neurotrauma. 2015 Feb 15;32(4):209-20. doi: 10.1089/neu.2014.3506. Epub 2014 Dec 29. Review.

Supplemental Content

Support Center